Jigna Shah

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

Leisha A. Emens, Francisco J. Esteva, Mark Beresford et al. · The Lancet Oncology · 2020 · 363 citations

Breast Oncology, Oncology, Pharmacology +7

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

Clifford A. Hudis, Charles Swanton, Yelena Y. Janjigian et al. · Breast Cancer Research · 2013 · 102 citations · Full text

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study

Ian E. Krop, Seock‐Ah Im, Carlos H. Barrios et al. · Journal of Clinical Oncology · 2021 · 62 citations · Full text

Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

Leisha A. Emens, Francisco J. Esteva, Mark Beresford et al. · Annals of Oncology · 2019 · 55 citations · Full text

Breast Oncology, Oncology, Inhibitor Atezolizumab +9

Nanoneuromedicine for management of neurodegenerative disorder

Nitin Dwivedi, Jigna Shah, Vijay Mishra et al. · Journal of Drug Delivery Science and Technology · 2018 · 43 citations

Nanoparticles, Nanomedicine, Neurodegenerative Diseases +7